JP2014523906A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523906A5 JP2014523906A5 JP2014519502A JP2014519502A JP2014523906A5 JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5 JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- drug
- defensins
- agent
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 21
- 229940079593 drug Drugs 0.000 claims 18
- 241000124008 Mammalia Species 0.000 claims 16
- 108050002883 beta-defensin Proteins 0.000 claims 16
- 102000012265 beta-defensin Human genes 0.000 claims 16
- 102000000541 Defensins Human genes 0.000 claims 9
- 108010002069 Defensins Proteins 0.000 claims 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 9
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 210000001072 colon Anatomy 0.000 claims 4
- 210000004443 dendritic cell Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010009887 colitis Diseases 0.000 claims 3
- 230000008595 infiltration Effects 0.000 claims 3
- 238000001764 infiltration Methods 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 102000046699 human CD14 Human genes 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 101710177030 Beta-defensin 10 Proteins 0.000 claims 1
- 102100039829 Beta-defensin 110 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 210000001731 descending colon Anatomy 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 102000055647 human CSF2RB Human genes 0.000 claims 1
- 102000049262 human DEFB4A Human genes 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000001599 sigmoid colon Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11173351 | 2011-07-08 | ||
| EP11173351.5 | 2011-07-08 | ||
| US201161506437P | 2011-07-11 | 2011-07-11 | |
| US61/506,437 | 2011-07-11 | ||
| PCT/EP2012/063137 WO2013007596A2 (en) | 2011-07-08 | 2012-07-05 | Oral treatment of inflammatory bowel disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017008251A Division JP6251827B2 (ja) | 2011-07-08 | 2017-01-20 | 炎症性腸疾患の経口治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523906A JP2014523906A (ja) | 2014-09-18 |
| JP2014523906A5 true JP2014523906A5 (enExample) | 2015-08-20 |
| JP6219277B2 JP6219277B2 (ja) | 2017-10-25 |
Family
ID=47506622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519502A Active JP6219277B2 (ja) | 2011-07-08 | 2012-07-05 | 炎症性腸疾患の経口治療 |
| JP2017008251A Active JP6251827B2 (ja) | 2011-07-08 | 2017-01-20 | 炎症性腸疾患の経口治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017008251A Active JP6251827B2 (ja) | 2011-07-08 | 2017-01-20 | 炎症性腸疾患の経口治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9217021B2 (enExample) |
| EP (1) | EP2729159B1 (enExample) |
| JP (2) | JP6219277B2 (enExample) |
| ES (1) | ES2637286T3 (enExample) |
| WO (1) | WO2013007596A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2750727A1 (en) | 2008-07-18 | 2010-01-21 | Novozymes Adenium Biotech A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
| US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
| KR101590452B1 (ko) | 2015-05-20 | 2016-02-02 | 중앙대학교 산학협력단 | 펩타이드 defb124를 유효성분으로 포함하는 면역증강 및 암 예방 또는 치료용 약학적 조성물 |
| WO2017027411A1 (en) * | 2015-08-07 | 2017-02-16 | The Regents Of The University Of California | Compositions and methods for inhibiting pro-inflammatory cytokine gene expression |
| JP6890135B2 (ja) * | 2016-01-26 | 2021-06-18 | ディフェンシン セラピューティクス エーピーエス | 腸内微生物叢を調節するための方法 |
| KR102465341B1 (ko) * | 2016-04-29 | 2022-11-09 | 디펜신 테라퓨틱스 에이피에스 | 간, 담관 및 췌장 장애의 치료 |
| EP3552632B1 (en) | 2016-12-07 | 2023-07-12 | Stelic Institute & Co., Inc. | Medicinal composition for treating and preventing inflammatory bowel disease |
| AU2017376400A1 (en) | 2016-12-13 | 2019-06-20 | Novozymes A/S | Methods for treating inflammatory conditions of the lungs |
| US20200316172A1 (en) * | 2017-11-10 | 2020-10-08 | Defensin Therapeutics Aps | Maturation of mucosal defense and gut/lung function in the preterm infant |
| EP3713590B1 (en) * | 2017-11-24 | 2025-05-07 | Defensin Therapeutics ApS | Human beta 2 defensin for use in the prevention and treatment of graft-versus-host-disease |
| KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| BR112021006643A8 (pt) * | 2018-10-09 | 2022-12-06 | B Schaal Justin | Composições e métodos para aumentar capacidade de distribuição sistêmica, tolerância e eficácia de peptídeos macrocíclicos catiônicos |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| DE19824484A1 (de) * | 1998-06-02 | 1999-12-09 | Bayer Ag | Festkörperreiche Polyurethandispersionen mit hoher Applikationssicherheit |
| DE19957043A1 (de) | 1999-11-26 | 2001-06-07 | Forssmann Wolf Georg | Neue Defensine |
| US7338936B2 (en) | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| FR2841556B1 (fr) | 2002-07-01 | 2007-07-20 | Centre Nat Rech Scient | Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments |
| US20060115480A1 (en) | 2002-12-19 | 2006-06-01 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
| US20070207209A1 (en) | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| GB0514482D0 (en) | 2005-07-14 | 2005-08-17 | Ares Trading Sa | Protein |
| WO2007081486A2 (en) * | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
| CA2676483A1 (en) | 2006-01-24 | 2007-08-02 | University Of Maryland Biotechnology Institute | Surface-layer protein coated microspheres and uses thereof |
| JP5491396B2 (ja) | 2007-09-11 | 2014-05-14 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのデフェンシンペプチドの使用 |
| CA2750727A1 (en) * | 2008-07-18 | 2010-01-21 | Novozymes Adenium Biotech A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
| NZ590469A (en) | 2008-07-18 | 2012-08-31 | Novozymes Adenium Biotech As | Treatment of rheumatoid arthritis with human beta defensins (1-4) |
| AU2009272680A1 (en) | 2008-07-18 | 2010-01-21 | Novozymes Adenium Biotech A/S | Treatment of inflammatory diseases with mammal beta defensins |
| JP5468007B2 (ja) * | 2008-09-10 | 2014-04-09 | 旭硝子株式会社 | 新規なプロスタグランジンｉ２誘導体 |
| JP2011121887A (ja) * | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP4620169B1 (ja) | 2010-01-28 | 2011-01-26 | 株式会社三和化学研究所 | 有機酸重合体を有効成分とするクローン病の予防又は治療剤 |
| US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
| US20130052213A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
-
2012
- 2012-07-05 US US14/131,364 patent/US9217021B2/en active Active
- 2012-07-05 EP EP12746034.3A patent/EP2729159B1/en active Active
- 2012-07-05 ES ES12746034.3T patent/ES2637286T3/es active Active
- 2012-07-05 JP JP2014519502A patent/JP6219277B2/ja active Active
- 2012-07-05 WO PCT/EP2012/063137 patent/WO2013007596A2/en not_active Ceased
- 2012-07-06 US US13/542,747 patent/US20130172235A1/en not_active Abandoned
-
2015
- 2015-11-16 US US14/942,307 patent/US9833495B2/en active Active
-
2017
- 2017-01-20 JP JP2017008251A patent/JP6251827B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523906A5 (enExample) | ||
| Liang et al. | Therapeutic roles of polysaccharides from Dendrobium Officinaleon colitis and its underlying mechanisms | |
| Luo et al. | Effects of lactate in immunosuppression and inflammation: Progress and prospects | |
| Tao et al. | Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin | |
| Pham et al. | Strategies for the design of orally bioavailable antileishmanial treatments | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| JP2011225596A5 (enExample) | ||
| AR081948A2 (es) | USO DE b DEFENSINAS DE MAMIFEROS PARA LA MANUFACTURA DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS DEL INTESTINO | |
| Wang et al. | Role of crosstalk between glial cells and immune cells in blood-brain barrier damage and protection after acute ischemic stroke | |
| US20180353474A1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| JP2013544244A5 (enExample) | ||
| RU2013127793A (ru) | Противовоспалительные композиции | |
| JP2011520980A5 (enExample) | ||
| Li et al. | Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity | |
| Sagnak et al. | Predictive Value of Urinary Interleukin-8 Cutoff Point for Recurrences After Transurethral Resection Plus Induction Bacillus Calmette-Guérin Treatment in Non–Muscle-Invasive Bladder Tumors | |
| Goh et al. | Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine | |
| EP3538132B1 (en) | Rectal insulin for treatment of inflammatory bowel diseases | |
| CN106668034A (zh) | L‑岩藻糖在治疗消化道病变的药品和保健品中应用 | |
| Khiong et al. | Inhibition of NF-κB pathway as the therapeutic potential of red fruit (Pandanus conoideus Lam.) in the treatment of inflammatory bowel disease | |
| CN102488699B (zh) | 芍药苷在制备防治肺纤维化药物中的应用 | |
| Vaishnavi | Management of Recurrent Apthous stomatitis-A Review | |
| Gao et al. | Tripterygium wilfordii polyglycosidium ameliorates pouchitis induced by dextran sulfate sodium in rats | |
| Gurvits et al. | Eczema herpeticum in pregnancy | |
| Zhai et al. | Inflammatory Dermatosis in HIV/AIDS Patients | |
| CN113209104B (zh) | Jak3抑制剂在制备治疗急性呼吸窘迫综合症药物中的应用 |